Speaker Name: Dr. Carolyn F. Deacon, Professor, Dept. of Biomedical Sciences, Panum Institute, University of Copenhagen, Denmark.

Explore this session to:

• Understand the incretin-based development of DPP-4 inhibitors and their mechanism of enhancing endogenous GLP-1 activity in T2DM.
• Review differences among DPP-4 inhibitors in dosing, metabolism, renal adjustment, hepatic use, and ADA/EASD guideline positioning.
• Interpret major clinical trial findings on CV safety, HF hospitalization, and renal outcomes.
• Evaluate ADA/EASD guideline recommendations for combining DPP-4 inhibitors with metformin, SGLT2 inhibitors, TZDs, and insulin.
• Gain insight into how generic DPP-4 inhibitors may improve affordability, second-line use, and access in routine T2DM care.